You are here: Home » News-IANS » Health-Medicine
Business Standard

Novel compound to tackle Type-2 diabetes found

IANS  |  New York 

Scientists have deployed a new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

The finding by the Scripps Research Institute (TSRI), US, may lead to a new type of diabetes treatment by enabling researchers quickly find drug candidates that activate cellular receptors in desired ways.

"In principle, we can apply this technique to hundreds of other receptors like the one we targeted in this study to find disease treatments that are more potent and have fewer side effects than existing therapies," explained Patricia H McDonald, an assistant professor at TSRI.

For the study, the team used the technique to target a receptor linked to Type-2 diabetes.

The GLP-1 receptor, as it is known, is expressed by insulin-producing "beta cells" in the pancreas.

Several drugs that activate this receptor are already approved for treating Type-2 diabetes.

In this case, the team's aim was to find a molecule that activates the GLP-1 receptor in a unique way.

Using the new technology, researchers eventually isolated one molecule called P5 that potently and selectively activated the GLP-1 receptor's G-protein pathway.

An initial test in healthy mice showed that P5 worked well at boosting glucose tolerance.

The team will now look for opportunities to develop P5 into a new diabetes drug.

The study appeared in the journal Nature Communications.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, December 08 2015. 10:44 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU